NEW YORK, NY, Sept. 4 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Dr. John Savin as its Vice President.
Dr. Savin will work closely with the CEO to direct GENova's growth in its business of identifying and acquiring potential drug targets and then subsequently outsourcing them to partners who can successfully usher them through clinical trials and then bring them to market.
"I am honoured to guide GENova as it positions itself as a leader in the expeditious development of innovative drugs," said Dr. Savin. "I am confident that the GENova business model will deliver new and effective therapies for patients while maximizing value for shareholders."
About John Savin, B.Sc, Ph.D., MBA
Mr. Savin builds on his 20 years experience in marketing and finance to provide strategic direction in the commercialisation and funding of innovative science on behalf of high-potential companies. His previous role was CEO of Physiomics, a systems biology company that he founded. Physiomics entered collaborations with companies like Bayer and Cyclacel, and developed a sophisticated product to optimize cancer therapeutic development. His company listed on AIM in 2004.
Prior to that, Savin worked for investment bank Gerrard Group as a pharmaceutical and biotechnology investment analyst, soon becoming a Director and a top-10-ranked City analyst. In this role, he worked with corporate finance on venture capital, many IPOs, secondary fund raising, restructuring and due diligence. Other experience includes being a Senior Consultant working at Board level with Glaxo, Zeneca, the MRC and Cabinet Office and DTi looking at issues such as the commercialization of humanized monoclonals and the strategic impact of the human genome project; and servi
|SOURCE GENova Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved